CureVac 宣布季节性流感疫苗开发计划的有前景的中期数据。 CureVac Announces Promising Interim Data from Seasonal Influenza Vaccine Development Program.

CureVac 的季节性流感候选疫苗在第 2 阶段中期数据中显示出良好的结果，显示所有编码的季节性流感病毒株的抗体滴度均有所提高，并且超过了获得许可的对照疫苗对甲型流感病毒株的滴度。 CureVac's seasonal flu vaccine candidate demonstrates promising results in Phase 2 interim data, showing boosted antibody titers for all encoded seasonal influenza strains and exceeding licensed comparator vaccines' titers for influenza A strains. 该候选药物编码了世界卫生组织推荐的所有四种流感病毒株的抗原，并且具有可接受的安全性。 The candidate encodes antigens for all four WHO-recommended flu strains and has an acceptable safety profile. 增强针对乙型流感病毒株的免疫反应的进一步优化将在其他第二阶段研究中进行测试。 Further optimizations for enhancing immune responses against influenza B strains will be tested in additional Phase 2 studies.